2/5
09:15 am
gri
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
High
Report
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
2/4
07:13 pm
gri
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights [Yahoo! Finance]
High
Report
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights [Yahoo! Finance]
2/4
08:45 am
gri
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
Low
Report
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
1/31
01:33 am
gri
High
Report
1/28
08:45 am
gri
GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF
High
Report
GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF
1/21
04:23 pm
gri
GRI Bio announces 1-for-28 reverse share split [Seeking Alpha]
Medium
Report
GRI Bio announces 1-for-28 reverse share split [Seeking Alpha]
1/21
04:01 pm
gri
GRI Bio Announces Reverse Stock Split
Medium
Report
GRI Bio Announces Reverse Stock Split
1/8
08:00 am
gri
GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621
High
Report
GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621
12/12
04:05 pm
gri
GRI Bio Announces Closing of $8.0 Million Public Offering
Medium
Report
GRI Bio Announces Closing of $8.0 Million Public Offering
12/11
09:15 am
gri
GRI Bio Announces Pricing of $8,000,000 Million Public Offering
High
Report
GRI Bio Announces Pricing of $8,000,000 Million Public Offering
12/10
04:05 pm
gri
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
High
Report
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
12/8
08:07 am
gri
GRI Bio (NASDAQ:GRI) had its price target raised by analysts at Ascendiant Capital Markets from $35.00 to $36.00. They now have a "buy" rating on the stock.
High
Report
GRI Bio (NASDAQ:GRI) had its price target raised by analysts at Ascendiant Capital Markets from $35.00 to $36.00. They now have a "buy" rating on the stock.